Evaluation of Single Doses of GSK962040 in Critically Ill Patients With Enteral Feed Intolerance

NCT01039805 · clinicaltrials.gov ↗

PHASE2

Phase

COMPLETED

Status

34

Enrollment

INDUSTRY

Sponsor class

Conditions

Gastroparesis

Interventions

DRUG: GSK962040 (50 mg)
DRUG: Placebo
DRUG: GSK962040 (75 mg)

Sponsor

GlaxoSmithKline